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Abstract Vitronectin is the carrier protein of plasminogen activator inhibitor 1 (PAI-1). We used a well-characterized panel of anti-human PAI- 
monoclonal antibodies (MoAbs) to localize the vitronectin-binding site on PAI-I. By employing a direct vitronectin/PAI-1 binding assay and two 
vitronectin-dependent i hibition assays, we demonstrate that the anti-PAI- MoAbs CLB-5, CLB-10, CLB-2C8 and 11, directed against different 
epitopes in the region between amino acids 110 and 145, prevent he interaction of PAI- with vitronectin. We conclude that the region between amino 
acids 110 and 145 of PAI- harbours an important determinant for the interaction with vitronectin. 
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1. Introduction 
Plasminogen activator inhibitor 1 (PAI-l), a member of the 
serine protease inhibitor (‘serpin’) family [ 141, is a major regu- 
latory protein of the fibrinolytic system [5]. Serpins act as a 
pseudo-substrate: the Pl-Pl’ peptide bond of the reactive cen- 
ter is contained within an exposed ‘stressed’ loop that acts as 
a ‘bait’ for the protease [6,7]. The interaction between the reac- 
tive center and the catalytic moiety of the protease results in a 
tight binding, typified by the formation of an equimolar, in- 
active SDS-stable complex. The target specificity of a serpin is 
mainly determined by the nature of the reactive center Pl resi- 
due. This is illustrated, e.g., by the properties of a PAI- mutant 
protein, having a methionine instead of the genuine arginine 
residue at the Pl position (PAI- R346M) [8], having a lO,OOO- 
fold lower rate of association with tissue-type plasminogen 
activator (t-PA) than ‘wild-type’ PAI- 1. 
It is conceivable that the physiologically relevant configura- 
tion of PAI- in plasma [9,10], in the subendothelial matrix [l l] 
and in releasates of platelets [12], is as a complex with its carrier 
protein vitronectin. This interaction stabilizes the inhibitory 
activity [lo] without altering the second-order association rate 
(k,) with t-PA [13]. Surprisingly, in the presence of vitronectin, 
the inhibitory property of the virtually inactive mutant PAI- 
R346M towards t-PA is vastly improved [8]. In addition, the 
interaction between PAI- and vitronectin endows the inhibitor 
with thrombin-inhibitory properties as evidenced by a 200-fold 
increase of the k, and the formation of SDS-stable thrombin- 
PAI- complexes [14,1.5]. The significance of the interaction 
between thrombin and PAI- in the presence of vitronectin has 
been demonstrated by using matrices of cultured endothelial 
cells as a source of vitronectin-PAI- complexes [16]. 
Apart from vitronectin, we have recently reported that the 
glycosaminoglycan heparin can also act as an obligatory cofac- 
tor for the inhibition of thrombin by PAI- [17]. The molecular 
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interactions between thrombin, PAI- and heparin have been 
described in some detail [18,19]. In contrast, the interaction 
between PAI-1, thrombin and vitronectin has not been exten- 
sively studied. The present study was undertaken to better 
define the area on PAI- involved in the interaction with vitro- 
nectin. By employing several approaches, we provide evidence 
that the region between the amino acid residues 110 and 145 
harbours an important determinant for the interaction between 
PAI- and vitronectin. 
2. Materials and methods 
2.1. Materials 
Wild-type PAI- and PAI- R346M were purified as described [8]. 
Active PAI- (kindly provided by Dr. T.M. Reilly, DuPont de Ne- 
mours, Wilmington, DE) was labeled with “‘1 using the Bolton-Hunter 
method as described before [20], resulting in a specific radioactivity of 
0.2 pCi/pg protein. Two-chain Bowes melanoma t-PA (910,000 IUlmg) 
was obtained from Biopool (# 1268403; Umea, Sweden). Purified 
human thrombin was provided by Dr. K. Mertens (Central Laboratory 
of the Blood Transfusion Service, The Netherlands). Active-site titra- 
tion with p-nitrophenyl p’-guanidinobenzoate [21] yielded a concentra- 
tion of 5.0 mg/ml. Thrombin was radiolabeled with IlZ5 using the Io- 
dogen method, resulting in a specific radioactivity of 1.6@/pg protein. 
Vitronectin was purified from human plasma to apparent homogeneity 
[22]. The protein concentration of the purified preparation was deter- 
mined, assuming an extinction coefficient at 280 nm of E,, = 13.0 and 
a molecular weight of 75,000 [23]. Unfractionated heparin from porcine 
intestinal mucosa (# H-3125, Co1 29F-0314; specific activity 178 units/ 
mg, average molecular weight 15,000-18,000), was purchased from 
Sigma (St. Louis, MO). Murine anti-human PAI- MoAbs were ob- 
tained from different sources: hybridoma cells producing the MoAbs 
CLB-5, CLB-10, CLB-16, CLB-8H2 and CLB-2C8 were isolated and 
purified as described [24]. The MoAb MAI- was obtained as purified 
IgG from Biopool (Umea, Sweden). The MoAbs M3 and 11 were a gift 
of Dr. B. Holte (Monozyme, Charlottenlund, Denmark). The final 
concentration of all antibodies was determined by measuring the opti- 
cal density at 280 nm (1 O.D. unit is 0.75 mg/ml [25]). The murine 
MoAb VN7, directed against vitronectin was produced and character- 
ized as described [26]. The synthetic substrates H-o-isoleucyl-prolyl- 
arginine-p-nitroanilide (S2288) and H-o-phenylalanyl-pipecolyl- 
arginyl-p-nitroanilide (S2238) were obtained from Chromogenix 
(Gothenburg, Sweden). 
2.2. Activation of PAI- (variant) and determination of the activity 
Wild-type PAI- or PAI- R346M was activated by an incubation 
for 2 h at room temperature in 6 M guanidinium-HCl [27]. The dena- 
turant was removed by overnight dialysis at 4°C against TST-buffer 
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(20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 0.1% Tween-80). Increasing 
amounts of activated wild-type PAI- or PAI- R346M were incubated 
for 1 h at 37°C in a total volume of 50 ul with 2.5 nM two-chain t-PA 
in TST-buffer, in the presence or absence of 40 nM vitronectin. Then, 
200 ~1 0.5 mM S2288 in TST-buffer was added and the residual t-PA 
activity was determined from a linear plot of the increase of the optical 
density at 405 nm versus time, using a Titertek Twinreader (Flow 
Laboratories, Irvine, UK). 
2.3. Dose-dependent effect of various MoAbs on the 
‘zSI-labeled-PAI-llvitronectin interaction 
The anti-vitronectin MoAb VN7 (1 ,& SO@/well in 0.1 M NaHCO,, 
pH 8.6) was coated overnight at 4°C in wells of a microtiter plate (Nunc 
Maxisorp, Gibco BRL, Paisley, UK). Wells coated with 2% (w/v) bo- 
vine serum albumin (BSA)/PBS served as a negative control. The wells 
were washed with distilled water and blocked for 1 h at 37’C with 3% 
(w/v) BSA/PBS. After washing with TBST-buffer (50 mM Tris-HCl 
(pH 7.4), 150 mM NaCl, 0.05% Tween-20), the wells were preincubated 
with [‘251]PAI-1 (40,000 counts per min/well) and increasing concentra- 
tions of different MoAbs in TBSB-buffer (50 mM Tris-HCl (pH 7.4), 
150 mM NaCl, 1% (w/v) BSA) for 15 min at room temperature. Subse- 
quently, after addition of 100 ng vitronectin/well the plate was incu- 
bated for 90 min at 37°C. The mixtures were removed and the plate was 
extensively washed with TBST-buffer. Bound [‘ZSI]PAI-l/vitronectin 
complexes were eluted after addition of 200 ~1 2% (w/v) SDSmBST- 
buffer and incubation for 10 min at room temperature. The radioactiv- 
ity was determined in a gamma-counter, and expressed as the percent- 
age of maximal [‘251]PAI-l binding. Data were corrected for binding to 
BSA-coated wells. The experiments were performed at least four times. 
2.4. Inhibition of t-PA by PAI-I R346M and vitronectin i  the presence 
of different-anti-PA%1 MoAbs 
5 nM active PAI- R346M was incubated for 30 min at room temper- 
ature in 30 ~1 TST-buffer, containing 40 nM vitronectin and 0.5 & of 
either one of the anti-PAI- MoAbs. Subsequently, t-PA was added to 
a final concentration of 5 nM followed by an additional incubation of 
1 h at 37°C. Finally, 200 ~1 of 0.5 mM of S2288 was added and the 
residual t-PA activity was determined as described above. 
2.5. Inhibition of thrombin by wild-type PAI-I and vitronectin or heparin 
in the presence of different anti-PAI-I MoAbs 
5 nM active wild-type PAI- was incubated either with 40 nM vitro- 
nectin or with 1 U/ml heparin and with 0.5 pg (or a range of 0-l pg 
in case of the dose-response assay) of one of the anti-PAI- MoAbs as 
described above. After complex formation of PAI- with either one of 
the cofactors, 5 ~1 of 0.7 nM thrombin was added. After an incubation 
of 1 h at 37”C, the reaction was arrested by the addition of 200 ~1 of 
0.5 mM S2238 and the residual thrombin activity was determined as 
described above. 
Results and discussion 
3.1. Effect of different anti-PA&l MoAbs on [“‘I]PAI-1 
binding to vitronectin 
Previously, we described the properties of a panel of the 
anti-human PAI- MoAbs and determined the corresponding 
1 110 145 
4 I 235 
343 
epitopes on the protein [24]. A summary of relevant data on the 
anti-PAI- 1 MoAbs employed is outlined in Fig. 1. It should be 
noted that the corresponding epitopes, involved in the inhib- 
itory activity of PAI-1, are located in two distinct areas namely, 
encompassing the reactive center Pl-Pl’(R346-M347) and the 
region between residues 110 and 145 [24]. We devised a binding 
assay and avoided immobilization of either vitronectin or PAI- 
1, since such manipulations are known to induce irreversible 
conformational changes and inactivation [15]. To that end, 
[‘251]PAI-1 was preincubated with increasing concentrations of 
different anti-PAI- MoAbs followed by the addition of vitro- 
nectin. Formed [‘251]PAI-1/vitronectin complexes were then 
bound to coated anti-vitronectin MoAb VN7. [‘251]PAI-1 
bound to vitronectin is fully competed with a lOO-fold excess 
of unlabeled PAI- (data not shown). The generation of 
[‘251]PAI-1/vitronectin complexes is partially prevented by the 
presence of the anti-PAI- MoAbs CLB-10, CLB-2C8, CLB-5 
and 11 (53-66% competition), whereas none of the other 
MoAbs affects the interaction between [‘251]PAI-1 and vitro- 
nectin (EC,,, values are given in Table 1). Combinations of the 
inhibitory MoAbs did not further reduce the binding of PAI- 
1 to vitronectin. Significantly, the corresponding epitope for 
each of the inhibitory MoAbs is exclusively located in the area 
between amino-acid residues 110 and 145 of PAI-1, suggesting 
that PAI- contains a single binding site for vitronectin. How- 
ever, the observation that the indicated antibodies do not fully 
prevent complex formation does not exclude the presence of 
additional binding sites. Taken together, these data supports 
our conclusion that region 110 to 145 of PAI- harbors an 
essential determinant for the binary interaction with vitro- 
nectin. It should be noted that this area is also involved in the 
interaction of PAI- with serine proteases and with fibrin [24]. 
The importance of this site in ternary interactions, i.e. in the 
presence of serine proteases, will be subsequently assessed. 
3.2. Prevention of t-PA inhibition by PA&I R346M in the 
presence of vitronectin by anti-PAI-I MoAbs 
The inhibition of t-PA by PAI- is independent of the pres- 
ence of vitronectin [lo]. Remarkably, however, vitronectin con- 
verts a virtually inactive PAI- mutant (PAI- R346M) into a 
rather efficient inhibitor of t-PA [8]. This observation was ex- 
ploited to test the influence of selected anti-PAI- MoAbs in 
a ternary interaction, including t-PA, vitronectin and PAI- 
R346M, to gain insight into the cofactor-dependent inhibitory 
mechanism. We are particularly interested in the effect of 
MoAb CLB-10, since we showed before that MoAbs CLB-203, 
CLB-5 and 11 also directly prevented the interaction between 
Pl-Pl’ 
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Fig. 1. Position of epitopes of anti-PAI- MoAbs on PAI-1. The binding site on PAI- for the MoAbs has been determined as described [24] and 
are indicated by black bars. The positions of the amino acids, bordering the areas in which the binding sites are located, are given. The location of 
the epitope of the MoAbs 11 and MAI- may be slightly extended in one direction as indicated by the shaded areas. 
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PAI- and t-PA in the absence of vitronectin, in contrast to 
CLB-10 [24]. The effect of different anti-PAI- MoAbs on 
vitronectin-dependent t-PA inhibition was measured using an 
endpoint assay with the chromogenic substrate S2288. As a 
control, t-PA inhibition by wild-type PAI- in the absence of 
vitronectin was determined in the presence of different anti- 
PAI- MoAbs (data not shown; see [24]). As expected, inhib- 
itory MoAbs that map either around the reactive center (MAI- 
12) or within the 110-145 region (CLB-2C8,CLB-5, Il), also 
prevent inhibition of t-PA by PAI- R346M in the presence of 
vitronectin (Fig. 2, white bar). The presence of the antibody M3 
(or CLB-16, CLB-8H2: data not shown) does not affect the 
inhibition of t-PA by wild-type PAI- nor of t-PA by PAI- 
R346M in the presence of vitronectin. Clearly, the anti-PAI- 
MoAb CLB-10 completely prevented the inhibition of t-PA by 
PAI- 1 R346M in the presence of vitronectin (Fig. 2, white bar), 
but had no effect on the inhibition of t-PA by wild-type PAI- 
(data not shown; see [24]). These observations were confirmed 
by SDS-PAGE analysis of the formation of ‘serpin specific’, 
SDS-stable complexes between [‘251]labeled t-PA and PAI- 
R346M and prevention of complex formation by CLB-10 (data 
not shown). It is noteworthy that the virtually complete block- 
ade of the vitronectin-dependent inhibitory activity by CLB-10 
contrasts with the partial prevention of PAI-llvitronectin com- 
plex formation (see previous section). Apparently, the ternary 
interaction (and ultimately inhibition of t-PA) fully relies on the 
availability of the 1 lo-145 area of PAI- R346M to vitronectin, 
whereas other regions may contribute to the binary interaction, 
next to the 110-145 region. Consequently, we conclude that 
binary complexes of PAI- R346M and vitronectin are a pre- 
requisite for the ternary inhibition reaction with t-PA. 
3.3. Effect of anti-PAI-I MoAb CLB-10 on thrombin-inhibition 
by PAI- in the presence of either vitronectin or heparin 
We reported before that vitronectin, but also heparin, pro- 
vides PAI- with thrombin-inhibitory properties and increases 
k, at least two orders of magnitude [14,17]. Consequently, we 
incubated wild-type PAI- 1, vitronectin or heparin, thrombin 
and various anti-PAI- MoAbs and measured residual ami- 
dolytic thrombin activity by using the chromogenic substrate 
S2238 (Fig. 2, black and hatched bars, respectively). Obviously, 
the inhibitory MoAbs CLB-2C8, CLB-5, 11 and MAI- pre- 
vent thrombin inhibition by PAI- both in the presence of 
vitronectin or heparin (data are shown for CLB-2C8 with vitro- 
nectin (Fig. 2, black bar) and with heparin (Fig. 2, hatched 
bar)). The antibody M3 (and similarly CLB-16, CLB-8H2; data 
not shown), did not affect the inhibition of thrombin by PAI- 
in the presence of either cofactor, in accordance with their lack 
Table 1 
Maximal inhibition and EC,, values of various anti-PA&l MoAbs to 
prevent PAI-Uvitronectin binding 
MoAb Epitope Reduction binding EC& 
(area on PAL-l) (% f S.E.M.) (nM + S.E.M.) 
CLB-10 I IO-145 66 + 6.0 92.6 f 14.2 
CLB-2C8 1 IO-145 55 f 2.4 5.5 f 0.8 
CLB-5 I IO-145 53 + 6.4 10.4 * 1.9 
I1 1 IO-145 54 f 6.7 17.4 f 8.2 
M3 2355283 =O > 667 
CLB16 235-283 =o > 667 
CLB-8H2 235-283 =O > 667 
MAI- 320-379 =o > 2600 
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Fig. 2. Prevention of t-PA or thrombin inhibition by PAI- (variant) 
and vitronectin in the presence of different anti-PAI- MoAbs. The 
residual inhibition of t-PA or thrombin after incubation with PAI-I 
(variant) and vitronectin in the presence of different anti-PAI- MoAbs 
is presented. Inhibition of t-PA by PAI- R346M or inhibition of 
thrombin by wild-type PAI- and heparin or vitronectin in the absence 
of MoAbs is indicated by 100%. Results of the representative MoAbs 
M3, CLB-10 and CLB-2C8 are presented. Data are presented as the 
mean of at least two experiments, while error bars indicated the stand- 
ard deviation. Symbols: black bars, thrombin inhibition by wild- type 
PAI- and vitronectin: white bars. t-PA inhibition bv PAI- R346M 
and vitronectin; hatched bars, thrombin inhibition by -wild- type PAI- 
and heparin. 
of effect in the t-PA-based assays. MoAb CLB-10 fully pre- 
vented thrombin-inhibition in the presence of vitronectin, sim- 
ilarly as the effect of CLB-10 in the t-PA/PA1 R346M assay in 
the presence of this cofactor (Fig. 2, black bar). The anti-PAI- 1 
MoAb CLB-10 did not alter the inhibition of thrombin by 
PAI- in the presence of heparin, in agreement with the finding 
that the heparin-binding site does not coincide with the 1 lo-145 
area [18] (Fig. 2, hatched bar). In addition, we assessed the 
formation of SDS-stable complexes between [iz51]thrombin and 
PAI- in the presence of vitronectin or heparin and, in particu- 
lar, the effect of different anti-PAI- MoAbs on complex for- 
mation. Again, complex formation with vitronectin as cofactor 
is prevented in the presence of CLB-10 (and CLB-2C8 or MAI- 
12) but not in the presence of, e.g., M3 and CLB-16, whereas 
with heparin no effect is observed for CLB-10 (data not shown). 
From these results, we conclude inhibition of thrombin requires 
the full association of PAI- and vitronectin, mediated by the 
1 lo-145 area of PAI-1. This conclusion is in accordance with 
our recent observations that thrombin, PAI- and vitronectin 
form ternary complexes (M. van den Nieuwenhuizen and H. 
Pannekoek, manuscript in preparation). 
3.4. Quantitative analysis on the prevention of vitronectin- 
mediated inhibition of t-PA and thrombin by anti-PAI-I 
CLB-10 
We compared the amount of anti-PAI- MoAb CLB-10 re- 
quired to prevent PAI-Uvitronectin binding in either one of the 
assays employed. For that purpose, different concentrations of 
CLB-10 were applied in both vitronectin-dependent assays, 
measuring either t-PA-inhibition by PAI- R346M or throm- 
bin-inhibition by wild-type PAZ-l. The anti-PAI- MoAb M3 
of the same subclass as CLB-10 (IgG,) [24] was used as a 
control (Fig. 3). In accord with our previous results, no effect 
was detected with M3 in either one of the available assays. A 
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Fig. 3. Quantitative analysis on the prevention of vitronectin-mediated inhibition of t-PA and thrombin by anti-PAI-I CLB-10. The prevention of 
vitronectin-dependent t-PA inhibition by PAI R346M (panel A) or thrombin inhibition by PAI- using increasing amounts of the MoAb CLB-10 
is presented. MoAb M3 serves as a control. Symbols: l =MoAb CLB-10; A=MoAb M3. 
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dose-dependent prevention of the inhibition by CLB-10 was 
observed both for the interaction between t-PA, PAI- R346M 
and vitronectin and between thrombin, wild-type PAI- and 
vitronectin. When heparin was used as a cofactor for the in- 
hibition of thrombin by PAI-1, no influence of both of the 
MoAbs was observed (data not shown). Half-maximal inhibi- 
tion in the t-PA-based assay is obtained with approximately 
39.8 f 5 ng of MoAb CLB-10 (panel A), whereas about 
6.2 f 1.3 ng of the antibody is required for half-maximal inhibi- 
tion of the thrombin-based assay (panel B). The requirement 
of MoAb CLB-10 to achieve half-maximal inhibition in each 
of the vitronectin-dependent reactions matches with the estab- 
lished k, values, i.e. 8.1 x 10’ and 1.6x lo5 M-‘.s-’ for t-PA 
inhibition by PAI- R346M [8] and thrombin inhibition by 
PAI- [14], respectively. We conclude that the inhibition of 
both serine proteases heavily relies on the availability of the 
110-145 area on PAI- for vitronectin binding. 
3.5. Concluding remarks 
Our conclusion that the region between amino acids 110 and 
145 on PAI- harbors an essential determinant for vitronectin 
binding and, consequently, for vitronectin-dependent inhibi- 
tion of thrombin and t-PA inhibition by PAI- (R346M), is 
supported by preliminary data reported by Sane and Pad- 
manabhan [28]. These authors showed by ligand blotting that 
vitronectin binds to two overlapping, proteolytic fragments of 
PAI-1, sharing the region between amino acids 91 and 128. In 
addition, by constructing chimeric proteins of PAI- and the 
serpin plasminogen activator inhibitor 2, it was indicated that 
the region between amino acids 115 and 166 binds to vitro- 
nectin. Furthermore, during the preparation of this paper, 
Lawrence and collaborators [29] showed by using random- 
directed mutagenesis that the amino acid residues 55, 109, 110, 
116 and 123 of PAI- are involved in binding to (immobilized) 
vitronectin. Although our data and those of others [28,29] are 
indicative of a single vitronectin-binding site on PAI-1, we do 
not exclude the presence of other sites. First, although MoAb 
CLB-10 fully prevents thrombin- and t-PA inhibition, as out- 
lined here, it should be emphasized that the antibody only 
partially inhibits the direct binding of vitronectin to PAI-1. 
Second, a Scatchard analysis of the binding of vitronectin to 
PAI- suggested the presence of two binding sites [30]. A future 
localization of the epitopes of other MoAbs that prevent the 
binding of vitronectin to PAI- may resolve this enigma [31]. 
In previous studies, we have shown that the region between 
amino acid residues 110 and 145 of PAI- is involved in binding 
to several other components, namely to t-PA, urokinase and 
fibrin [24]. Examination of the three-dimensional structure of 
PAI- reveals that the region spanning amino acid residues 110 
and 145 is composed of the subdomains helix E, sheet Al and 
helix F [7,32]. It can be speculated that each of these juxtaposed 
subdomains might be responsible for the various interactions, 
although further experiments are required to substantiate this 
option. 
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